Login
A Cancer Test Has Investors Betting Big. But Will Insurers Pay?
An FDA panel backed Grail’s Galleri test. But the Medicare money the business depends on is far from guaranteed.
© Grail Inc.
© Getty Images
Reading view
The Peptide Boom That Isn’t About Your Muscles
The real opportunity is pill-form peptides that could hit big pharma’s most profitable franchises.
Trump Administration Shift Puts This Corner of Biotech Back in Favor
With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.
© Maansi Srivastava/The Washington Post/Getty Images
Trump Administration Shift Puts This Corner of Biotech Back in Favor
With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.
© Maansi Srivastava/The Washington Post/Getty Images
